New hope for liver cancer: drug combo targets patients who failed immunotherapy
NCT ID NCT07493668
First seen Mar 30, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tests whether adding the experimental drug fostrox to the standard drug lenvatinib can shrink tumors better than lenvatinib alone in people with advanced liver cancer that got worse after immunotherapy. About 80 adults will take pills daily or in cycles until their cancer progresses or side effects become too severe. The goal is to see if the combination improves response rates and helps guide future treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.